Connect with us

Business

There is opportunity brewing in these two warehouses

Published

on

January saw markets start the new year with strong gains, while February saw them stabilize. In the past two weeks, major indices have seen range-bound trading; Investor sentiment remains upbeat for the time being, but there is some skepticism about the long-term direction of stocks.

It is an environment that makes it difficult to find potential winners. What we need is a tool for navigating uncertainty. the Smart Score A tool, at TipRanks, is designed to do exactly that. Essentially, the tools collect and rank data – and then measure it against a set of 8 factors that are all known to be strong predictors of superior performance in the future. The smart score itself is a single-digit score, drawn from the dataset and presented on a scale of 1 to 10, from lowest to highest. The “perfect 10,” the highest possible percentage, indicates which stocks the stars have lined up for—and one investors should take a second look at.

We plunged in TipRanks Database to pull in details for two stocks that each show that “Perfect 10” Smart Score. According to the data, both are strong buys of stocks with plenty of upside potential. Let’s find out what else you recommend them, what underpins their smart results, and what the analysts think.

Rain Oncology, Inc. (rain)

Advertisement

We’ll start with Rain Oncology, formerly Rain Therapeutics. This is a clinical-stage biopharmaceutical company, looking for new anti-cancer precision drugs based on genetic matching of treatment to patient. The methodology is designed to maximize success while minimizing side effects.

The company currently has two drug candidates in the pipeline, Miladistan, which has several clinical trials underway, and RAD52, which is still undergoing preclinical research.

Milademetan hits the headlines here. The drug candidate’s leading clinical trial, the Mantra phase III trial in liposarcoma, has enrolled 160 patients and the company expects to release preliminary data during the second quarter of ’23, which unfortunately earlier this month, the company fell short of its previously expected first quarter reading.

This drug candidate is also in the MANTRA-2 study, a phase II trial of safety and efficacy in the treatment of enlarged MDM2 solid tumors in patients with advanced or metastatic disease. The study aimed to enroll 65 patients.

Advertisement

Late last month, the company published clinical data from its Phase I trials of Miladistan against a range of tumor types. The data published, in Journal of Clinical Oncologyshowed positive antitumor activity and tolerability profiles using intermittent dosing.

Financially, at the end of the third quarter, Rain had $90.7 million in cash and liquid assets. After the November earnings release, the company raised $50 million from a follow-up stock offering.

turned to Rain smart points, We found that the “Perfect 10” gets support from strong blogger and crowd sentiment, as well as hedge funds and insider buying. Initially, financial bloggers are 100% bullish on RAIN, while crowd wisdom shows a 54% positive trend over the past 30 days. In the second, corporate insiders bought more than $987,000 in shares in the past three months, while hedgers TipRanks tracks, increased holdings in RAIN by 3.7 million shares in the most recent quarter.

In this inventory’s coverage of the Roth MKM, Kumaraguru Raja takes a positive view of the delay in releasing milademetan data, writing, “We believe the delay is due to a lack of accumulation of events required 105 PFS (Progression-Free Survival) for the final pay-for-success analysis, and because likely to better performance of either experimental arm.We remain optimistic and expect milademetan to outperform trabectedin based on the historical PFS seen with trabectedin and milademetan PFS in a phase I trial…we believe that milademetan has a high chance in cancers where MDM2 and p53 are They are the two main drivers.”

To that end, along with a buy rating, Raja is giving RAIN shares a price target of $21, which implies a strong one-year upside potential of 121%. (To see Raja’s track record, click here.)

Advertisement

All seven recent analyst reviews on Rain stock are positive, giving the stock a consensus Strong Buy rating. RAIN is currently priced at $9.50 and the average price target of $19.43 implies a 104% upside in the next 12 months. (See Rain’s stock forecast at TipRanks.)

Capalita Bio (kappa)

Next up is Cabaletta Bio, another research-oriented biopharmaceutical company. Capalita’s research targets the treatment of autoimmune diseases, a class of diseases that has long defied effective treatment efforts. The company uses a cell therapy approach, building on the remarkable successes of T-cell therapies in fighting various types of cancer. Cabaletta works on chimeric autoimmune antigen receptor (CARTA) T cells, to create new therapeutic agents for intractable autoimmune diseases.

Cabaletta has been making some noise with its drug candidate CABA-201, which is described as a “newly designed all-human CD19 chimeric antigen receptor (CAR) containing a 4-1BB co-stimulatory domain.” Added to the pipeline last fall, this drug candidate has shown potential in treating conditions such as polymyositis, systemic sclerosis, rheumatoid arthritis, and other B-cell-related autoimmune diseases. Cabaletta is investigating this drug candidate under an exclusive worldwide license obtained from Nanjing IASO Biotherapeutics, and expects to submit an investigational new drug application to the FDA within 1H23.

The successful IND of CABA-201 will add this drug candidate to a clinical pipeline that already includes DSG3-CAART, an investigational treatment for mPV, mucous pemphigus vulgaris. This is a skin disease with few current treatment options, and DSG3-CAART was designed to attack infected antibodies without affecting uninfected B cells. The drug candidate is currently in Phase 1, and Cabaletta reported favorable safety data in October last year.

Turning to the financials, Capalita’s most recent quarterly report showed a cash balance of $85.9 million, and then, in December, the company announced a $35 million stock offering.

Advertisement

this company Smart Score Displays many positive metrics. Hedge fund managers bought this stock last quarter, to the tune of 2.9 million shares, while the wisdom of the crowd has shown a positive 9% increase in the last 30 days. Financial bloggers, who are usually somewhat volatile, were 100% bullish on CABA stock, and in terms of technologies, the company’s 12-month turnaround registered an impressive positive 213% momentum. All of this adds up to a perfect 10.

Analyst Michael Oles has looked at the details of investment bank Morgan Stanley’s Cabaletta, and sees the company’s upcoming regulatory filings as the main catalyst. Oles wrote of this development,[The] An IND file for CABA-201 is expected in 1H23, paving the way for preliminary Ph1 data in 1H24, which we expect to drive the upside. Our positive expectations are driven by a combination of: 1) the groundbreaking results from an academic study (reset of the immune system in 5/5 SLE patients) also using CD19 CAR-T, 2) the similar design of CABA201 (the same humanized CD19 binder 4) -1BB in terms of cost), and 3) a management team experienced in developing cellular therapies for autoimmune diseases. “

These comments support Ulz’s Overweight (or Buy) rating of CABA stock, and his $16 price target indicates his confidence in a 102% upside potential for the coming year. (To watch Owls’ record, click here.)

Cabaletta Bio picked up 5 analyst reviews recently, all of which are positive, making the consensus view here a Strong Buy. The stock is selling for $7.93 with an average price target of $13.80; This indicates a gain of 74% for the next year. (See Cabaletta stock forecasts at TipRanks.)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best stocks to buya newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Advertisement

Source link

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Rast’s accusations against Alec Baldwin were formally dismissed by Reuters

Published

on

By

© Reuters. FILE PHOTO: A view of the movie “Rust” playing at Bonanza Creek Ranch near Santa Fe, New Mexico, US January 20, 2023. REUTERS/Drone Base/File Photo

Written by Andrew Hay

TAOOS, New Mexico (Reuters) – Special prosecutors in New Mexico on Friday dropped charges against actor Alec Baldwin in the 2021 shooting of “Rust” cinematographer Halina Hutchins, referring to what many legal analysts described as a rationale for a prosecution. flawed jurisprudence.

A person close to prosecutors said the move followed new evidence of the gun Baldwin was carrying when he fired the shot that killed Hutchins while shooting the movie in Santa Fe, New Mexico.

This information undermined the prosecution’s case after a series of legal flops, leading them to dismiss the charges before a May hearing when a judge was to decide whether there was enough evidence to prosecute Baldwin and gunsmith “Rust” Hannah Gutierrez Reid.

Advertisement

“The case was dismissed without bias and the investigation is active and ongoing,” prosecutors Carey Morrissey and Jason Lewis said in a memo.

Prosecutors went on to charge Gutierrez Reed, 25, with manslaughter. She has said she held the live round in the gun thinking it was a dummy round. The preliminary hearing in her case has been postponed to August 9.

The dismissal of the same charge against Baldwin came after his attorney presented evidence last week that the copy of the .45 Colt Baldwin has used has been modified with new parts since being manufactured by Italian gunsmith FLL Pietta.

The information compromised the prosecution’s argument that the gun was in fully working condition and could only fire if Baldwin recklessly pulled the trigger, according to the person familiar with the case.

Special prosecutors have said they may re-file charges against Baldwin once new evidence is examined, though legal experts are skeptical.

Advertisement

“This very weak case against Baldwin should never have been brought in the first place,” said Ambrosio Rodriguez, a former district attorney with the District Attorney’s Office in Riverside County, California.

Filming for “Rust” resumed in Montana this week with many of the same lead actors, including Baldwin, and was expected to wrap up in May.

Rust Movie Productions (RMP) said in February that it would not resume filming in New Mexico, without giving a reason. A Santa Fe prosecutor charged Baldwin and others in January.

Source link

Advertisement
Continue Reading

Business

Leading news reporter Jill Christian dies at 83

Published

on

By

Gail Christian, who broke barriers as a black on-air reporter and came to national prominence at NBC News and PBS, died April 12 in Los Angeles. She was 83 years old.

Her wife, Lucy Debardelapine, said it was a complication from a recent bowel surgery.

Christian overcame a troubled youth—including a prison term for armed robbery—to end a career as a prominent television journalist and news executive in the 1970s and 1980s, an era when the industry was dominated by white men.

It became a visible presence in American living rooms with it coverage to NBC News on the trial of Patricia Hearst, the newspaper heiress who was kidnapped in 1974 by a gang of left-wing revolutionaries called the Symbionese Liberation Army, and who was convicted two years later for participating in a bank robbery with the group.

Advertisement

But for Ms. Christian, it wasn’t enough just to appear as a rare black face on the evening news.

She said in Interview with the Chicago Tribune In 1986. I felt that was the reason I was there. I didn’t resent it in the least. I felt then, as I feel now, that it is very dangerous for a group of people to live in a society in which they are not allowed to explain themselves.”

It has succeeded in this task with features like “A Country Called Watts”, An hour-long 1977 NBC News special that explored the efforts of residents of this Los Angeles neighborhood to come together and re-evaluate the bloody civil unrest that occurred in response to police brutality in 1965, rebuilding burned-out blocks in the face of perceived government indifference and continued police harassment.

Gary Gilson, former faculty director of a summer program for minority students at Columbia University’s Graduate School of Journalism, in a phone interview. “And her pioneering role as a black news reporter allowed black kids to see, many for the first time, an impressive person on television who looked like them. It gave them recognition and hope.”

After two years at NBC News, Ms. Christian became news director for public station KCET in her hometown of Los Angeles, where she created a “60 Minutes”-style investigative series called “28 Tonight” (the station was on channel 28).

Advertisement

The program featured several award-winning segments, including a segment on a banking scandal that harmed low-income communities and another on a chemical spill in Orange County that caused illnesses in the area, each of which won a Peabody Award.

In 1981 she moved to Washington, where she began nearly a decade as the news director for the Public Broadcasting Service.

“Since I’ve been in the business, I’ve always wanted to be one of the officers who goes out in that little room and decides what’s going to be covered and who’s going to cover it,” she said in a 1976 interview with the Los Angeles Times. “But at NBC, I never saw any women walk into that little room. Nor any minorities. I thought this was my chance.”

She added, “As Bobby Seale said,” referring to one of the founders of the Black Panther Party, “take the time.”

Jill Christian Jill Patricia Wells was born on February 20, 1940, in Los Angeles, one of four children of Edwin Wells, who worked on an assembly line for the Hughes Aircraft Company, and Lucille (Scruggs) Wells, who owned a cosmetology college. In the Leimert Park neighborhood of South Central Los Angeles. (She later adopted Christian, a name from her mother’s family, as her professional surname.)

Advertisement

Ms. Christian grew up in Venice, California, and spent three years studying world history at California State University, Los Angeles, before dropping out to join the Air Force in 1962. She was caught in a raging crowd after being discharged, and in 1965, was found guilty of Armed robbery after eroticism in a hotel.

The theft, which resulted in less than $100, led to her admission to the California Institute for Women in Chino for 18 months. Christian said in a 1976 interview with TV Guide. “I really didn’t need to do that. I had a loving family, unlike a lot of the others in prison. I was just kind of pushed out at the time.”

After she had served her time, a paroled colleague who was working as a switchboard operator at The San Francisco Examiner gave her a tip that the paper was planning to hire two black reporters to diversify its staff. Without any experience, Ms. Christian considered the opportunity far-reaching, but talked her way into the role of an apprentice by stretching the truth.

“I gave them this song and they danced around working on this little black paper that the Klan burned,” she told the Tribune.

In 1970, she participated in an 11-week summer program for minority students in broadcast journalism at Columbia. (Geraldo Rivera was a classmate.) Two years later, she was hired by local NBC affiliate KNBC. She worked there for six years before NBC News hired her.

Advertisement

Her tenure at PBS ended in 1989, shortly after the network found itself embroiled in controversy over the airing of a pro-Palestinian documentary, Days of Rage, which Ms. Christian had acquired and was responsible for vetting. A news report confirmed that the film was partially supported by undisclosed Arab funding, which was denied by the film’s producer.

In an interview with The New York Times, Ms. Christian said she quit PBS for other reasons. She said, “You’re burning because this is a no-win situation.” “You are silent when things are going well and angry when there are questions.”

She eventually settled in Palm Springs, California, with Mrs. DeBardelaben, whom she married in 2016. In 2003, the couple started the Palm Springs Women’s Jazz Festival.

In addition to Mrs. DeBardelaben, Mrs. Christian is survived by her grandson. Her daughter, Sunday Barrett, died in 2019.

While Ms. Christian kept quiet about her prison term early in her career, she finally decided to divulge it to a sympathetic NBC executive. “The guy just looked at me,” she recalls. He says: I don’t have enough problems. Do I have to listen to you? Get outta here.’ I didn’t hear another word.”

Advertisement

Source link

Continue Reading

Business

Economic mood and other investment stories you may have missed this week

Published

on

By

This week has been a tough bullish one. Here’s what investors saw:

  • Oil prices have given up most of the gains from the OPEC+ production cut.

  • The Philadelphia Fed Manufacturing Index hit a new low for this economic cycle and missed expectations. Other indicators from the Conference Board The leading economic indicator I also fell.

  • Initial jobless claims were a surprise to the upside for the fourth consecutive week.

  • Weak earnings and more caution emerged from freight operators JB Hunt and Union Pacific as well as auto retailer AutoNation. Netflix and Taiwan Semiconductor, a major supplier to Apple, also issued guidance warnings.

  • There have been more layoffs in Meta’s Cloroxwith reports of planned job cuts at Disney.

  • Tesla reported a quarterly gross margin loss recently price cuts.

The bottom line is that there is an ongoing negative shift in economic data, most likely as interest rates continue to rise in the economy. This is a red flag.

Oddly enough, however, investors can’t seem to jump into it judging by the resilience of the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average.

“The latest data is further evidence that there will be a recession in the US soon, which fits with our own view at DB Research that it is expected to happen later in the year,” Jim Reed, Deutsche Bank strategist wrote in the client note.

Advertisement

Good words of wisdom now.

Tesla CEO Elon Musk speaks to a visitor as he arrives to look at the Tesla Gigafactory construction on September 3, 2020, near Gruenheide, Germany. (Photo by Maja Hitij/Getty Images)

3 things you might have missed

1. The mood among AmEx cardholders: I met with American Express CEO Stephen Squarey, and he struck an optimistic tone about order trends.

“The economy is definitely divided, and I think at the lower end of the economy, we’re seeing some pressure, but we don’t have that,” Squirey said, adding that he sees strong demand for travel in the spring and summer. The call to travel lines up with what we’ve heard about this earnings season from Delta and United Airlines.

2. Elon Musk is following the storm. An interesting highlight from Tesla’s earnings call was when Elon Musk said he didn’t see the economy improving until 2024. The CEO predicted another year of “stormy economic weather” before “things start to get sunny in the spring of next year.”

Advertisement

Musk joins the likes of JPMorgan CEO Jamie Dimon in using weather to describe the economic outlook.

3. About this credit cost: In an exclusive on Yahoo Finance Live, Loretta Mester, President of the Federal Reserve Bank of Cleveland, tells Jane Schoneberger that there is only one direction for interest rates in the near term: higher.

“I think that, given the complexity of inflation, and given the still-strong job market, I think rates should go above the 5% level,” Mester said.

Loretta J.  Jim Urquhart

Loretta J. Jim Urquhart

C-Suite, quote of the week

“We are not seeing a significant drop in trade [among consumers]John Mueller, CEO of Procter & Gamble (PG) told Yahoo Finance Live. We are witnessing, if anything, more careful use of the product they purchased. So they might use half a sheet of a Bounty paper towel instead of a full sheet. But overall, again, just looking at the numbers, the consumer holds up very well.”

planner of the week

For those investors who are ignoring the dangers of the impending debt ceiling, here’s a helpful reminder from the macroeconomics team at Goldman Sachs on how markets will price in the 2011 debt ceiling debate:

Advertisement
Remember the debt ceiling debacle of 2011?

Remember the debt ceiling debacle of 2011?

Brian Suzy He is the Executive Editor of Yahoo Finance. Follow Suzy on Twitter @tweet and on linkedin. Deal tips, mergers, activist positions, or anything else? Email brian.sozzi@yahoofinance.com

Click here for the latest stock market news and in-depth analysis, including the events that move stocks

Read the latest financial and business news from Yahoo Finance



Source link

Advertisement
Continue Reading

Trending